Community Contributor
Member since 2023
Views
2k Total number of views
Fair Values Set
39 Total number of fair values set
Comments
0 Total number of comments
Followers
0 Total number of followers

No bio added yet

No link added
BMY logo
Bristol-Myers Squibb

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.Read more

View narrative
574
users have viewed this narrative
3users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
US$65
9.8% undervalued intrinsic discount
Fair Value
Profit Margin
14.81%
Future PE
22.23x
Price in 2030
US$87.86
MDT logo
Medtronic

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).Read more

View narrative
1.5k
users have viewed this narrative
10users have liked this narrative
5users have commented on this narrative
22users have followed this narrative
US$95
8.2% undervalued intrinsic discount
Fair Value
Revenue
5.15% p.a.
Profit Margin
13%
Future PE
27.57x
Price in 2030
US$141.16